title: Persistence of cardiovascular risk after rofecoxib discontinuation.
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Ross
authors.forename: David
authors.initials: D
authors.lastname: Madigan
authors.forename: Marvin A
authors.initials: MA
authors.lastname: Konstam
authors.forename: David S
authors.initials: DS
authors.lastname: Egilman
authors.forename: Harlan M
authors.initials: HM
authors.lastname: Krumholz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib